Author:
Adebahr Sonja,Bernhardt Denise
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. Adebahr S, Collette S, Shash E et al (2015) LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. Br J Radiol 88:20150036
2. AstraZeneca. A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515); clinicaltrials.gov; 2020 Mai [zitiert 31. 08. 2022]. Report No.: NCT03833154. Available online: https://clinicaltrials.gov/ct2/show/NCT03833154
3. Badra EV, Baumgartl M, Fabiano S et al (2021) Stereotactic radiotherapy for early stage non-small cell lung cancer: current standards and ongoing research. Transl Lung Cancer Res 10(4):1930–1949. https://doi.org/10.21037/tlcr-20-860
4. Bahig H, Filion E, Vu T et al (2016) Severe radiation pneumonitis after lung stereotactic ablative radiation therapy in patients with interstitial lung disease. Pract Radiat Oncol 6:367–374
5. Ball D, Mai GT, Vinod S et al (2019) Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol 20:494–503